CDK46 Inhibitor AE IDST
An Interactive Tool for Managing AEs With CDK4/6 Inhibitors for HR+, HER2– Breast Cancer

Released: April 11, 2025

Expiration: April 10, 2026

About This Tool & Disclaimer

An Interactive Tool for Managing AEs With CDK4/6 Inhibitors for HR+, HER2– Breast Cancer

Clinical Care Options, LLC, is grateful to Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP, and Laura Spring, MD, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in March/April 2025 and reflects the expert recommendations provided at that time.

The goal of the tool is to educate healthcare professionals on the optimal management of adverse events (AEs) associated with CDK4/6 targeted therapies that are used to treat patients with HR-positive, HER2-negative breast cancer.

A series of questions allow the users to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include whether CDK4/6 targeted therapy has been initiated, which CDK4/6 targeted therapy is being used, whether an AE is present or an invasive procedure is planned, and the type and severity of the AE if present.

It should be noted that these are not exclusive characteristics when managing AEs in patients with HR-positive, HER2-negative breast cancer who are receiving a CDK4/6 targeted therapy as part of systemic treatment. Other considerations that are not included in this tool, such as the presence of various comorbidities and any concurrent medications, should also be considered, when appropriate.

This tool assumes we have a “standard” patient with HR-positive, HER2-negative breast cancer who is considering or has already started CDK4/6 targeted therapy.

Based on the characteristics entered, the tool will display expert-based recommendations for that specific patient case.

For additional information on best practices in the management of patients with HR-positive, HER2-negative breast cancer who is considering or has already started a CDK4/6 targeted therapy, please go online for downloadable slides, on-demand webcasts, and podcasts on this topic.

© 2025 Clinical Care Options, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “An Interactive Tool for Managing AEs With CDK4/6 Inhibitors for HR+, HER2– Breast Cancer” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on the optimal management of AEs associated with CDK4/6 targeted therapies that are used to treat patients with HR-positive, HER2-negative breast cancer. The information provided is based on expert guidance of Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP, and Laura Spring, MD,.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “An Interactive Tool for Managing AEs With CDK4/6 Inhibitors for HR+, HER2– Breast Cancer” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2025 Clinical Care Options, LLC. All rights reserved.

Program Content